Mode
Text Size
Log in / Sign up
N/A Completed N=1,645

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

Source: ClinicalTrials.gov NCT00615914 ↗
Enrolled (actual)
1,645
Serious AEs
7.1%
Results posted
Nov 2010
Primary outcomePrimary: Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 42.4; 34.5; 7.2 percentage of participants

Summary

The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events
42.4; 34.5; 7.2 —
SECONDARY
Clinical Global Impression of Improvement
48; 561; 484; 209; 225 —
SECONDARY
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
-5.4 —
SECONDARY
Change From Baseline in Modified Hoehn & Yahr Rating Scale
-0.2 —

Eligibility Criteria

Inclusion Criteria

Patients with Parkinson's disease

Exclusion Criteria

Patients should have been treated according to the Japanese insert slip

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00615914). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search